Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor,

Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments
  - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and
                             Envision Healthcare

PR Newswire

NEW YORK, November 27, 2013

NEW YORK, November 27, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences Inc. (NASDAQ: GILD), WellPoint Inc. (NYSE: WLP), Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), Forest Laboratories Inc. (NYSE: FRX),
and Envision Healthcare Holdings, Inc. (NYSE: EVHC). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On November 22, 2013, Gilead Sciences, Inc. (Gilead) announced that Sovaldi,
its investigational once-daily oral nucleotide analogue polymerase inhibitor,
has received supportive opinion from the Medicinal Products for Human Use
(CHMP), to be approved for the treatment of chronic hepatitis C virus (HCV)
infection in adults in combination with other agents. According to the
Company, the CHMP's recommendation will now be reviewed by the European
Commission for approval, and if approved, Sovaldi could be available in the EU
in Q1 2014. The Full Research Report on Gilead Sciences Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/9898_GILD

--

WellPoint Inc. Research Report

On November 11, 2013, WellPoint Inc. (WellPoint) announced that it has been
recognized as one of the 2014 Top 100 Military Friendly Employer® by Victory
Media, publisher of G.I. Jobs and Military Spouse. The Company informed that
it has achieved 74th position on the list and that it has made into the list
for the fifth year. Karin Sarratt, Vice President of Talent Management and
Chief Diversity Officer at WellPoint said, "Being named to the list of Top
Military Friendly Employers for the last five years acknowledges the
significant efforts that WellPoint has dedicated to establishing and improving
best practices for recruiting and retaining veterans. We know that veterans
and our associates serving in the National Guard and Reserve bring tremendous
value to our organization; their contributions and commitment make us stronger
as a company so we can succeed at transforming healthcare with trusted and
caring solutions." The Full Research Report on WellPoint Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/64cd_WLP

--

Questcor Pharmaceuticals, Inc. Research Report

On November 22, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that
the Company has been recognized with an "Everyday Hero" award by the NephCure
Foundation. According to the Company, the award marks its 'tireless efforts'
to advance science and research in the field of nephrology as well as to
promote educational efforts related to the treatment of proteinuria in
patients with kidney disease who are suffering from nephrotic syndrome. Steve
Cartt, Chief Operating Officer of Questcor, said, "Questcor is honored to have
received this recognition from NephCure. We feel strongly about supporting
research and educational initiatives that will positively impact patients with
kidney disease and the nephrology community as a whole. Our flagship product,
Acthar, is an FDA-approved prescription medication that is used by an
increasing number of nephrologists to induce remission of proteinuria in
patients who are suffering from certain types of nephrotic syndrome. We are
proud to support the nephrology community through the funding of research,
education and other important initiatives." The Full Research Report on
Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/a415_QCOR

--

Forest Laboratories Inc. Research Report

On November 21, 2013, Forest Laboratories, Inc. (Forest Laboratories) and
Gedeon Richter Plc. (Gedeon Richter) jointly announced that the U.S. Food and
Drug Administration (FDA) has issued a complete response letter in relation to
the New Drug Application (NDA) for cariprazine, an atypical antipsychotic for
the treatment of schizophrenia and for the acute treatment of manic or mixed
episodes associated with bipolar I disorder in adults. According to the
Company, FDA in its letter has acknowledged that cariprazine clearly
demonstrated effectiveness in the treatment of schizophrenia and mania
associated with bipolar disorder. However, the Agency indicated more
information, including additional clinical trial data, would be needed. Dr.
Marco Taglietti, President, Forest Research Institute, said, "The unmet
medical need for schizophrenia and bipolar disorder remains high. We are
committed to pursuing novel treatment options like cariprazine to address
patient needs. Forest and Gedeon Richter plan to meet with the FDA in the very
near future to discuss the complete response letter and define a path
forward." The Full Research Report on Forest Laboratories Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/ea24_FRX

--

Envision Healthcare Holdings, Inc. Research Report 

On November 13, 2013, Envision Healthcare Holdings Inc. (EVHC) and Envision
Healthcare Corporation (Envision Corporation) (both together, Envision
Healthcare) announced three new appointments. The Company informed that it has
appointed Mark V. Mactas to the Boards of Directors of EVHC as well as
Envision Corporation and will serve as a member of the Compliance and
Compensation Committees. Envision Healthcare also announced the appointment of
Nicholas A. Poan as Chief Accounting Officer and Controller, effective
immediately, and that of William Huron as the Company's Chief Compliance
Officer. The Full Research Report on Envision Healthcare Holdings, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/4b31_EVHC

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.